Dihexa vs FGL

Evidence-based comparison. Updated 2026.

Dihexa and FGL are both research-stage neuropeptides targeting memory and synaptic plasticity, but they operate through distinct receptor pathways. Dihexa modulates NGF and BDNF signaling via AT4 receptor agonism, making it a stronger candidate for potency-focused cognitive enhancement research. FGL mimics NCAM to activate FGFR pathways, with a comparatively stronger focus on neuroprotection and neuroinflammation reduction. Researchers prioritizing raw cognitive enhancement may lean toward Dihexa; those targeting neuroprotective or anti-inflammatory endpoints may prefer FGL.

Side by side

	Dihexa	FGL
Evidence	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data
Regulatory	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only
Benefits	Enhances memory and learning capacity Supports neuroplasticity and synaptic growth Improves cognitive processing speed Promotes neuroprotection against damage Enhances NGF and BDNF signaling	Enhances memory formation and retention Promotes neural plasticity and synaptic growth Supports neuroprotection against excitotoxicity Improves cognitive function and learning capacity Reduces neuroinflammation in brain tissue
Dosage	50-100 mcg, 1x daily	1-5 mg, 1x daily
Route	Subcutaneous	Subcutaneous
Category	Cognitive Enhancement	Cognitive Enhancement

Full research page

Dihexa

Full research page

FGL

Which should you choose

Dihexa acts primarily through AT4 receptor agonism to amplify NGF and BDNF signaling, while FGL mimics NCAM to engage fibroblast growth factor receptors. These distinct receptor targets mean each peptide reaches overlapping but non-identical aspects of synaptic plasticity and neuroprotection.

Choose Dihexa when

Research focus is on maximizing memory formation and learning capacity through potent neurotrophic signaling amplification.
The study design requires engagement of both NGF and BDNF pathways simultaneously via a single compound.
Long-term potentiation enhancement is a primary endpoint, where Dihexa's AT4 agonism has demonstrated notable preclinical effect sizes.

Choose FGL when

Research focus includes neuroinflammation reduction alongside plasticity, as FGL has shown evidence of attenuating inflammatory processes in brain tissue.
The study context involves excitotoxic injury models, where NCAM-mimetic signaling through FGFR has demonstrated neuroprotective relevance.
A shorter or more established peptide sequence is preferred, as FGL's NCAM-mimetic design has a defined structural basis in adhesion molecule biology.

Stacking Dihexa and FGL is not a well-documented research practice, but their complementary receptor targets (AT4 versus FGFR) suggest a theoretical rationale for combined use in models requiring both neurotrophic amplification and neuroprotection, though no clinical or robust preclinical data currently supports this combination.

Questions people ask

Do Dihexa and FGL work through the same receptors, and does that affect how they might interact if combined?

No, they operate through distinct receptor systems. Dihexa acts as an AT4 receptor agonist to upregulate NGF and BDNF, while FGL activates fibroblast growth factor receptors by mimicking NCAM. This receptor-level separation means they are unlikely to compete directly, though their downstream effects on synaptic plasticity and LTP converge. No peer-reviewed data currently characterizes their pharmacological interaction in combination.

Which peptide has a faster onset of observable effect in cognitive research models?

Dihexa has been reported in preclinical studies to produce cognitive effects at relatively low doses with notable potency, suggesting a comparatively rapid mechanistic engagement via AT4 signaling. FGL's effects in animal studies are generally observed over repeated dosing periods, consistent with its role in gradually reinforcing synaptic architecture through FGFR activation. Direct head-to-head onset comparisons have not been published.

Is one of these peptides more relevant than the other for neuroinflammation-related research models?

FGL holds a clearer research profile in neuroinflammation contexts, with studies indicating it can reduce inflammatory markers in brain tissue alongside its plasticity-promoting effects. Dihexa's neuroprotective profile is more broadly attributed to neurotrophic support rather than direct anti-inflammatory action. For study designs where neuroinflammation is a primary variable, FGL represents the more targeted choice based on available preclinical evidence.

Can Dihexa and FGL be considered interchangeable for memory enhancement research, or do they serve different experimental purposes?

They are not interchangeable. While both enhance memory and synaptic plasticity in preclinical models, Dihexa's mechanism is rooted in amplifying endogenous neurotrophic factor signaling, whereas FGL's mechanism is structural, mimicking an adhesion molecule to engage growth factor receptors. Researchers should select based on the specific pathway or outcome being interrogated. Studies requiring NGF or BDNF pathway data should favor Dihexa; those examining cell adhesion-related plasticity should favor FGL.

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide